Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
| Revenue (Most Recent Fiscal Year) | $88.82B |
| Net Income (Most Recent Fiscal Year) | $14.07B |
| PE Ratio (Current Year Earnings Estimate) | 14.82 |
| PE Ratio (Trailing 12 Months) | 15.69 |
| PEG Ratio (Long Term Growth Estimate) | 2.15 |
| Price to Sales Ratio (Trailing 12 Months) | 4.25 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.86 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 12.02 |
| Pre-Tax Margin (Trailing 12 Months) | 29.78% |
| Net Margin (Trailing 12 Months) | 24.42% |
| Return on Equity (Trailing 12 Months) | 33.46% |
| Return on Assets (Trailing 12 Months) | 13.30% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.26 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.03 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.49 |
| Inventory Turnover (Trailing 12 Months) | 2.27 |
| Book Value per Share (Most Recent Fiscal Quarter) | $29.69 |
| Earnings per Share (Most Recent Fiscal Quarter) | $2.77 |
| Earnings per Share (Most Recent Fiscal Year) | $9.98 |
| Diluted Earnings per Share (Trailing 12 Months) | $8.99 |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Common Shares Outstanding | 2.41B |
| Free Float | 2.40B |
| Market Capitalization | $379.41B |
| Average Volume (Last 20 Days) | 7.34M |
| Beta (Past 60 Months) | 0.41 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.16% |
| Percentage Held By Institutions (Latest 13F Reports) | 69.55% |
| Annual Dividend (Based on Last Quarter) | $5.20 |
| Dividend Yield (Based on Last Quarter) | 3.30% |